Does the media favor NRIX or CTMX?

In the previous week, CytomX Therapeutics had 1 more articles in the media than Nurix Therapeutics. MarketBeat recorded 4 mentions for CytomX Therapeutics and 3 mentions for Nurix Therapeutics. CytomX Therapeutics' average media sentiment score of 1.45 beat Nurix Therapeutics' score of 1.09 indicating that CytomX Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SLS or CTMX?

In the previous week, SELLAS Life Sciences Group had 1 more articles in the media than CytomX Therapeutics. MarketBeat recorded 5 mentions for SELLAS Life Sciences Group and 4 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 1.45 beat SELLAS Life Sciences Group's score of 0.82 indicating that CytomX Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CTMX or VRDN?

In the previous week, CytomX Therapeutics and CytomX Therapeutics both had 4 articles in the media. CytomX Therapeutics' average media sentiment score of 1.45 beat Viridian Therapeutics' score of 1.14 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viridian Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CTMX or CDNA?

In the previous week, CytomX Therapeutics had 1 more articles in the media than CareDx. MarketBeat recorded 4 mentions for CytomX Therapeutics and 3 mentions for CareDx. CytomX Therapeutics' average media sentiment score of 1.45 beat CareDx's score of 0.91 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CareDx 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CTMX or RARE?

In the previous week, Ultragenyx Pharmaceutical had 6 more articles in the media than CytomX Therapeutics. MarketBeat recorded 10 mentions for Ultragenyx Pharmaceutical and 4 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 1.45 beat Ultragenyx Pharmaceutical's score of -0.19 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ultragenyx Pharmaceutical 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

CytomX Therapeutics (CTMX) Competitors

$3.29 -0.06 (-1.79%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.30 +0.00 (+0.15%)

As of 09/11/2026 07:59 PM Eastern

Compare

CTMX vs. NRIX, SLS, VRDN, CDNA, and RARE

Should you buy CytomX Therapeutics stock or one of its competitors? CytomX Therapeutics's main competitors and comparable companies include Nurix Therapeutics (NRIX), SELLAS Life Sciences Group (SLS), Viridian Therapeutics (VRDN), CareDx (CDNA), and Ultragenyx Pharmaceutical (RARE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CytomX Therapeutics compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and CytomX Therapeutics (NASDAQ:CTMX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

CytomX Therapeutics has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$36.77M	70.85	-$264.46M	-$3.45	N/A
CytomX Therapeutics	$76.20M	9.41	-$17.37M	-$0.50	N/A

In the previous week, CytomX Therapeutics had 1 more articles in the media than Nurix Therapeutics. MarketBeat recorded 4 mentions for CytomX Therapeutics and 3 mentions for Nurix Therapeutics. CytomX Therapeutics' average media sentiment score of 1.45 beat Nurix Therapeutics' score of 1.09 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.8% of CytomX Therapeutics shares are held by institutional investors. 6.7% of Nurix Therapeutics shares are held by company insiders. Comparatively, 3.8% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Nurix Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market.

Nurix Therapeutics presently has a consensus target price of $34.21, suggesting a potential upside of 36.31%. CytomX Therapeutics has a consensus target price of $11.90, suggesting a potential upside of 261.70%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

CytomX Therapeutics has a net margin of -435.21% compared to Nurix Therapeutics' net margin of -928.44%. CytomX Therapeutics' return on equity of -38.46% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
CytomX Therapeutics	-435.21%	-38.46%	-30.33%

Summary

CytomX Therapeutics beats Nurix Therapeutics on 14 of the 17 factors compared between the two stocks.

How does CytomX Therapeutics compare to SELLAS Life Sciences Group?

SELLAS Life Sciences Group (NASDAQ:SLS) and CytomX Therapeutics (NASDAQ:CTMX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

SELLAS Life Sciences Group has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -435.21%. SELLAS Life Sciences Group's return on equity of -35.91% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-35.91%	-33.34%
CytomX Therapeutics	-435.21%	-38.46%	-30.33%

SELLAS Life Sciences Group currently has a consensus target price of $10.00, suggesting a potential downside of 13.42%. CytomX Therapeutics has a consensus target price of $11.90, suggesting a potential upside of 261.70%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CytomX Therapeutics is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by company insiders. Comparatively, 3.8% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

SELLAS Life Sciences Group has a beta of 2.52, suggesting that its share price is 152% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market.

In the previous week, SELLAS Life Sciences Group had 1 more articles in the media than CytomX Therapeutics. MarketBeat recorded 5 mentions for SELLAS Life Sciences Group and 4 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 1.45 beat SELLAS Life Sciences Group's score of 0.82 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CytomX Therapeutics has higher revenue and earnings than SELLAS Life Sciences Group. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.21	N/A
CytomX Therapeutics	$76.20M	9.41	-$17.37M	-$0.50	N/A

Summary

CytomX Therapeutics beats SELLAS Life Sciences Group on 11 of the 16 factors compared between the two stocks.

How does CytomX Therapeutics compare to Viridian Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Viridian Therapeutics (NASDAQ:VRDN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

CytomX Therapeutics has a beta of 2.14, meaning that its stock price is 114% more volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

CytomX Therapeutics presently has a consensus price target of $11.90, indicating a potential upside of 261.70%. Viridian Therapeutics has a consensus price target of $38.54, indicating a potential upside of 81.44%. Given CytomX Therapeutics' higher possible upside, equities analysts plainly believe CytomX Therapeutics is more favorable than Viridian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

CytomX Therapeutics has higher revenue and earnings than Viridian Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	9.41	-$17.37M	-$0.50	N/A
Viridian Therapeutics	$71.13M	33.83	-$342.60M	-$3.37	N/A

CytomX Therapeutics has a net margin of -435.21% compared to Viridian Therapeutics' net margin of -505.86%. CytomX Therapeutics' return on equity of -38.46% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-435.21%	-38.46%	-30.33%
Viridian Therapeutics	-505.86%	-72.97%	-42.80%

67.8% of CytomX Therapeutics shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by insiders. Comparatively, 2.4% of Viridian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, CytomX Therapeutics and CytomX Therapeutics both had 4 articles in the media. CytomX Therapeutics' average media sentiment score of 1.45 beat Viridian Therapeutics' score of 1.14 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viridian Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CytomX Therapeutics beats Viridian Therapeutics on 12 of the 16 factors compared between the two stocks.

How does CytomX Therapeutics compare to CareDx?

CytomX Therapeutics (NASDAQ:CTMX) and CareDx (NASDAQ:CDNA) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

In the previous week, CytomX Therapeutics had 1 more articles in the media than CareDx. MarketBeat recorded 4 mentions for CytomX Therapeutics and 3 mentions for CareDx. CytomX Therapeutics' average media sentiment score of 1.45 beat CareDx's score of 0.91 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CareDx	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CytomX Therapeutics has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market. Comparatively, CareDx has a beta of 2.43, meaning that its share price is 143% more volatile than the broader market.

CareDx has a net margin of 24.23% compared to CytomX Therapeutics' net margin of -435.21%. CareDx's return on equity of 2.87% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-435.21%	-38.46%	-30.33%
CareDx	24.23%	2.87%	2.17%

CytomX Therapeutics has higher earnings, but lower revenue than CareDx. CytomX Therapeutics is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	9.41	-$17.37M	-$0.50	N/A
CareDx	$379.80M	6.85	-$21.35M	$2.07	24.28

67.8% of CytomX Therapeutics shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by company insiders. Comparatively, 2.4% of CareDx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CytomX Therapeutics currently has a consensus target price of $11.90, indicating a potential upside of 261.70%. CareDx has a consensus target price of $51.20, indicating a potential upside of 1.87%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe CytomX Therapeutics is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
CareDx	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.63

Summary

CytomX Therapeutics beats CareDx on 9 of the 16 factors compared between the two stocks.

How does CytomX Therapeutics compare to Ultragenyx Pharmaceutical?

CytomX Therapeutics (NASDAQ:CTMX) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 3.8% of CytomX Therapeutics shares are held by insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CytomX Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	9.41	-$17.37M	-$0.50	N/A
Ultragenyx Pharmaceutical	$673M	2.09	-$575M	-$5.84	N/A

CytomX Therapeutics has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

Ultragenyx Pharmaceutical has a net margin of -81.79% compared to CytomX Therapeutics' net margin of -435.21%. CytomX Therapeutics' return on equity of -38.46% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-435.21%	-38.46%	-30.33%
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%

CytomX Therapeutics currently has a consensus price target of $11.90, indicating a potential upside of 261.70%. Ultragenyx Pharmaceutical has a consensus price target of $36.63, indicating a potential upside of 156.16%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe CytomX Therapeutics is more favorable than Ultragenyx Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Ultragenyx Pharmaceutical	1 Sell rating(s)	9 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.52

In the previous week, Ultragenyx Pharmaceutical had 6 more articles in the media than CytomX Therapeutics. MarketBeat recorded 10 mentions for Ultragenyx Pharmaceutical and 4 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 1.45 beat Ultragenyx Pharmaceutical's score of -0.19 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ultragenyx Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

CytomX Therapeutics beats Ultragenyx Pharmaceutical on 9 of the 16 factors compared between the two stocks.

Get CytomX Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTMX vs. The Competition

Export

Metric	CytomX Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$729.96M	$3.84B	$7.13B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-6.58	14.25	275.24	25.29
Price / Sales	9.41	1,473.16	656.02	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	5.67	15.12	10.33	6.20
Net Income	-$17.37M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-11.32%	-4.34%	-3.32%	-2.35%
1 Month Performance	-5.73%	-0.02%	-0.41%	-2.77%
1 Year Performance	64.50%	40.64%	19.21%	7.63%

CytomX Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTMX CytomX Therapeutics	2.8819 of 5 stars	$3.29 -1.8%	$11.90 +261.7%	+57.4%	$729.96M	$76.20M	N/A	170
NRIX Nurix Therapeutics	2.995 of 5 stars	$25.78 -1.6%	$34.21 +32.7%	+172.8%	$2.72B	$83.98M	N/A	300	Positive News
SLS SELLAS Life Sciences Group	0.3931 of 5 stars	$13.34 +1.0%	$10.00 -25.0%	+511.1%	$2.67B	N/A	N/A	10
VRDN Viridian Therapeutics	2.8635 of 5 stars	$23.16 +0.3%	$38.54 +66.4%	+8.1%	$2.61B	$70.85M	N/A	50	Positive News
CDNA CareDx	2.4875 of 5 stars	$50.11 +0.6%	$47.75 -4.7%	+271.5%	$2.58B	$379.80M	24.21	740

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTMX) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CytomX Therapeutics (CTMX) Competitors

CTMX vs. NRIX, SLS, VRDN, CDNA, and RARE

How does CytomX Therapeutics compare to Nurix Therapeutics?

Summary

How does CytomX Therapeutics compare to SELLAS Life Sciences Group?

Summary

How does CytomX Therapeutics compare to Viridian Therapeutics?

Summary

How does CytomX Therapeutics compare to CareDx?

Summary

How does CytomX Therapeutics compare to Ultragenyx Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX vs. The Competition

CytomX Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CytomX Therapeutics (CTMX) Competitors

CTMX vs. NRIX, SLS, VRDN, CDNA, and RARE

How does CytomX Therapeutics compare to Nurix Therapeutics?

Which has stronger earnings & valuation, NRIX or CTMX?

Does the media favor NRIX or CTMX?

Do insiders & institutionals hold more shares of NRIX or CTMX?

Which has more risk and volatility, NRIX or CTMX?

Do analysts rate NRIX or CTMX?

Is NRIX or CTMX more profitable?

Summary

How does CytomX Therapeutics compare to SELLAS Life Sciences Group?

Is SLS or CTMX more profitable?

Do analysts prefer SLS or CTMX?

Do institutionals & insiders hold more shares of SLS or CTMX?

Which has more volatility and risk, SLS or CTMX?

Does the media favor SLS or CTMX?

Which has higher earnings & valuation, SLS or CTMX?

Summary

How does CytomX Therapeutics compare to Viridian Therapeutics?

Which has more volatility and risk, CTMX or VRDN?

Do analysts recommend CTMX or VRDN?

Which has higher earnings and valuation, CTMX or VRDN?

Is CTMX or VRDN more profitable?

Do institutionals and insiders have more ownership in CTMX or VRDN?

Does the media prefer CTMX or VRDN?

Summary

How does CytomX Therapeutics compare to CareDx?

Does the media prefer CTMX or CDNA?

Which has more risk & volatility, CTMX or CDNA?

Is CTMX or CDNA more profitable?

Which has preferable earnings & valuation, CTMX or CDNA?

Do institutionals & insiders have more ownership in CTMX or CDNA?

Do analysts recommend CTMX or CDNA?

Summary

How does CytomX Therapeutics compare to Ultragenyx Pharmaceutical?

Do institutionals and insiders have more ownership in CTMX or RARE?

Which has preferable earnings & valuation, CTMX or RARE?

Which has more risk and volatility, CTMX or RARE?

Is CTMX or RARE more profitable?

Do analysts recommend CTMX or RARE?

Does the media refer more to CTMX or RARE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX vs. The Competition

CytomX Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools